I
Imbiss Schlemmerkiste
● Website: imbiss.de
Business Health Check
Free comprehensive assessment for Imbiss Schlemmerkiste
16
Critical
Financial Health0/100
Company Size0/100
Growth Potential0/100
Stability & Risk60/100
Data Completeness35/100
Monitor Imbiss Schlemmerkiste
Get real-time alerts when this company's health score changes. Track competitors, suppliers, and clients.
Try SCALA OS →
🔔 Get notified when this score changes
Free. No spam. Unsubscribe anytime.
💼
Manage this company in your CRM
Import into S.C.A.L.A. CRM with AI agent SARA. From €97/mo.
Risk Overview
● Revenue: No data
● Profitability: Unknown
● Status: active
Key People
Executive data not available. Get Enterprise Report →
Corporate Structure
Corporate group data requires LEI. Get Enterprise Report →
Ownership
Detailed ownership available in Get Enterprise Report →
Top Competitors
Companies in the same sector and revenue range
| Company | Revenue | Employees | Score |
|---|---|---|---|
| Imbiss Schlemmerkiste | N/A | N/A | N/A |
| Bundesagentur für Arbeit | > €1B | 1,000+ | 80 |
| merck surface solutions | > €1B | 1,000+ | 80 |
| goneo gmbh | > €1B | 1,000+ | 80 |
| sandvik p&p - part of sandvik materials technology | > €1B | 1,000+ | 80 |
| unser heimatbäcker holding gmbh/lila bäcker | > €1B | 1,000+ | 80 |
Certifications & Standards
No certifications on record. Claim this profile to add certifications (ISO 9001, ISO 14001, SOC 2, etc.).
Credit Worthiness
Fair
Acceptable financial standing
Latest News
Loading...
Company Details
| Address | Walther-Blohm-Str. 5-7, 21279 |
| Source | overture_eu |
Website preview — imbiss.de
Similar Companies in Wenzendorf
Bundesagentur für Arbeit €9.7B
merck surface solutions €3.3B
goneo gmbh €4.5B
sandvik p&p - part of sandvik materials technology €1.7B
unser heimatbäcker holding gmbh/lila bäcker €1.2B
Stadt Gelsenkirchen €1.2B
colibrium additive - a ge aerospace company €4.5B
kws-lochow gmbh €2.3B
Gebr. Heinemann €2.2B
truck driver job project €1.9B
kistenpfennig ag €1.2B
coalesce vanderbilt - meharry center of excellence in sickle cell disease €3.3B